Want to see BSX full AI Analyst Report?

Boston Scientific (BSX) Stock Forecast & Price Target

4,568 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BSX Analyst Ratings

Strong Buy

21 Buy

3 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$62.86

▲(42.06% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $62.86 with a high forecast of $89.00 and a low forecast of $50.00. The average price target represents a 42.06% change from the last price of $44.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","107":"$107","58.25":"$58.3","74.5":"$74.5","90.75":"$90.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.86363636363637,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$62.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,58.25,74.5,90.75,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.06,46.59384615384616,50.12769230769231,53.66153846153846,57.19538461538462,60.72923076923077,64.26307692307692,67.79692307692308,71.33076923076923,74.86461538461538,78.39846153846153,81.93230769230769,85.46615384615384,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.06,44.583356643356645,46.10671328671329,47.630069930069936,49.15342657342658,50.67678321678322,52.20013986013986,53.723496503496506,55.24685314685315,56.77020979020979,58.29356643356644,59.816923076923075,61.340279720279725,{"y":62.86363636363637,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.06,43.59384615384616,44.12769230769231,44.66153846153846,45.19538461538462,45.72923076923077,46.26307692307692,46.79692307692308,47.330769230769235,47.864615384615384,48.39846153846154,48.93230769230769,49.466153846153844,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 86,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.06,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$89.00

Average Price Target$62.86

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

$60→$61

Buy

37.85%

Upside

Reiterated

07/31/26

Boston Scientific: Buy Rating Reaffirmed as Analyst Trims Price Target to $61 but Sees Strong Long-Term Growth Reacceleration

David Toung

Argus Research

―

Hold

―

Downgraded

07/30/26

Boston Scientific downgraded to Hold from Buy at ArgusBoston Scientific downgraded to Hold from Buy at Argus

Pito Chickering

Deutsche Bank

$75→$60

Buy

35.59%

Upside

Reiterated

07/30/26

Deutsche Bank Remains a Buy on Boston Scientific (BSX)

Suraj Kalia

Oppenheimer

$85

Buy

92.09%

Upside

Reiterated

07/30/26

Oppenheimer Keeps Their Buy Rating on Boston Scientific (BSX)

Mike Kratky

Leerink Partners

$74→$60

Buy

35.59%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $60 from $74 at LeerinkBoston Scientific price target lowered to $60 from $74 at Leerink

Richard Newitter

Truist Financial

$62→$57

Buy

28.81%

Upside

Assigned

07/30/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and The Ensign Group (NASDAQ: ENSG)

Robbie Marcus

J.P. Morgan

$80→$56

Buy

26.55%

Upside

Assigned

07/30/26

Boston Scientific price target lowered to $56 from $80 at JPMorganBoston Scientific price target lowered to $56 from $80 at JPMorgan

Vijay Kumar

Evercore ISI

$65→$55

Buy

24.29%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $55 from $65 at Evercore ISIBoston Scientific price target lowered to $55 from $65 at Evercore ISI

David Rescott

Robert W. Baird

$64→$56

Buy

26.55%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $56 from $64 at BairdBoston Scientific price target lowered to $56 from $64 at Baird

Josh Jennings

TD Cowen

$61→$56

Buy

26.55%

Upside

Reiterated

07/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC) and Boston Scientific (NYSE: BSX)

William Plovanic

Canaccord Genuity

$70→$66

Buy

49.15%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $66 from $70 at CanaccordBoston Scientific price target lowered to $66 from $70 at Canaccord

Patrick Wood

UBS

$74→$67

Buy

51.41%

Upside

Reiterated

07/30/26

Morgan Stanley Reaffirms Their Buy Rating on Boston Scientific (BSX)

Michael Matson

Needham

$57

Buy

28.81%

Upside

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Rezolute (NASDAQ: RZLT) and Boston Scientific (NYSE: BSX)

Larry Biegelsen

Wells Fargo

$55→$50

Hold

12.99%

Upside

Reiterated

07/29/26

Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)

Travis Steed

Bank of America Securities

$61→$54

Buy

22.03%

Upside

Reiterated

07/29/26

Analysts Conflicted on These Healthcare Names: Boston Scientific (NYSE: BSX), Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

$60→$61

Buy

37.85%

Upside

Reiterated

07/31/26

Boston Scientific: Buy Rating Reaffirmed as Analyst Trims Price Target to $61 but Sees Strong Long-Term Growth Reacceleration

David Toung

Argus Research

―

Hold

―

Downgraded

07/30/26

Boston Scientific downgraded to Hold from Buy at ArgusBoston Scientific downgraded to Hold from Buy at Argus

Pito Chickering

Deutsche Bank

$75→$60

Buy

35.59%

Upside

Reiterated

07/30/26

Deutsche Bank Remains a Buy on Boston Scientific (BSX)

Suraj Kalia

Oppenheimer

$85

Buy

92.09%

Upside

Reiterated

07/30/26

Oppenheimer Keeps Their Buy Rating on Boston Scientific (BSX)

Mike Kratky

Leerink Partners

$74→$60

Buy

35.59%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $60 from $74 at LeerinkBoston Scientific price target lowered to $60 from $74 at Leerink

Richard Newitter

Truist Financial

$62→$57

Buy

28.81%

Upside

Assigned

07/30/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and The Ensign Group (NASDAQ: ENSG)

Robbie Marcus

J.P. Morgan

$80→$56

Buy

26.55%

Upside

Assigned

07/30/26

Boston Scientific price target lowered to $56 from $80 at JPMorganBoston Scientific price target lowered to $56 from $80 at JPMorgan

Vijay Kumar

Evercore ISI

$65→$55

Buy

24.29%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $55 from $65 at Evercore ISIBoston Scientific price target lowered to $55 from $65 at Evercore ISI

David Rescott

Robert W. Baird

$64→$56

Buy

26.55%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $56 from $64 at BairdBoston Scientific price target lowered to $56 from $64 at Baird

Josh Jennings

TD Cowen

$61→$56

Buy

26.55%

Upside

Reiterated

07/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC) and Boston Scientific (NYSE: BSX)

William Plovanic

Canaccord Genuity

$70→$66

Buy

49.15%

Upside

Reiterated

07/30/26

Boston Scientific price target lowered to $66 from $70 at CanaccordBoston Scientific price target lowered to $66 from $70 at Canaccord

Patrick Wood

UBS

$74→$67

Buy

51.41%

Upside

Reiterated

07/30/26

Morgan Stanley Reaffirms Their Buy Rating on Boston Scientific (BSX)

Michael Matson

Needham

$57

Buy

28.81%

Upside

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Rezolute (NASDAQ: RZLT) and Boston Scientific (NYSE: BSX)

Larry Biegelsen

Wells Fargo

$55→$50

Hold

12.99%

Upside

Reiterated

07/29/26

Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)

Travis Steed

Bank of America Securities

$61→$54

Buy

22.03%

Upside

Reiterated

07/29/26

Analysts Conflicted on These Healthcare Names: Boston Scientific (NYSE: BSX), Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months

Marie ThibaultBTIG

Success Rate

27/40 ratings generated profit

Average Return

+1.86%

Copying Marie Thibault's trades and holding each position for 3 Months would result in 67.50% of your transactions generating a profit, with an average return of +1.86% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

39/53 ratings generated profit

Average Return

+12.18%

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.18% per trade.

2 Years

Jayson BedfordRaymond James

Success Rate

41/53 ratings generated profit

Average Return

+22.86%

Copying Jayson Bedford's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +22.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BSX has received 64 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 62.86.

Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.81 with a range of $0.80 to $0.84. The previous quarter’s EPS was $0.86. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.26B with a range of $5.20B to $5.30B. The previous quarter’s sales results were $5.44B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.64% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 62.86.

What is BSX’s upside potential, based on the analysts’ average price target?

Boston Scientific has 42.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BSX a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Strong Buy which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.

What is Boston Scientific’s price target?

The average price target for Boston Scientific is 62.86. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $89.00 ,the lowest forecast is $50.00. The average price target represents 42.06% Increase from the current price of $44.25.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of BSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Boston Scientific (BSX) Stock Forecast & Price Target

BSX Analyst Ratings

BSX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

BSX Analyst Recommendation Trends

BSX Financial Forecast

BSX Earnings Forecast

BSX Sales Forecast

BSX Stock Forecast FAQ

Detailed List of Analyst Forecasts